Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
MGUS-like myeloma pts who undergo ASCT achieve stronger responses, defined as CR and MRD-ve vs. intermediate and MM-like groups; also independent predictor of CR, MRD- and PFS, decreasing likelihood of PD/death by 40-60%:”
Title: Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation
Authors: Borja Puertas, Elena Alejo, José J. Pérez-Morán, Fe Serra-Toral, Irene Padilla, Julio Dávila-Valls, Aránzazu García-Mateo, José María Alonso-Alonso, Roberto Hernández, Carlos Aguilar-Franco, Rosa López-López, Alfonso García-Coca, Alberto Cantalapiedra-Diez, Abelardo Bárez, Beatriz Rey-Búa, Lucía López-Corral, Juan Flores-Montero, M. Belén Vidriales-Vicente, Norma C. Gutiérrez, Verónica González-Calle, Fernando Escalante, Noemi Puig, Maria-Victoria Mateos
Read the Full Article on Clinical Lymphoma, Myeloma and Leukemia
More posts featuring Robert Orlowski.
